Radiation monotherapy as regional treatment for lymph node‐positive Merkel cell carcinoma
- 16 February 2010
- Vol. 116 (7), 1783-1790
- https://doi.org/10.1002/cncr.24919
Abstract
BACKGROUND: Merkel cell carcinoma (MCC) is an aggressive cutaneous malignancy with a high risk of lymph node involvement. To the authors' knowledge, few data have been published to date regarding the optimal regional therapy for lymph node‐positive patients. This cohort study was performed to analyze the outcomes of patients with lymph node‐positive MCC treated with lymph node irradiation as definitive therapy compared with completion lymphadenectomy (CLND). METHODS: Fifty patients with lymph node involvement of MCC at presentation and adequate follow‐up data were included in this analysis. Forty‐three of these patients were enrolled and followed prospectively. Twenty‐six patients presented with microscopic lymph node disease, and 24 patients presented with palpable lymph node involvement. RESULTS: Regional control for patients with microscopically involved lymph nodes was 100% regardless of treatment modality—definitive lymph node irradiation (n = 19) or CLND ± radiotherapy (n = 7) with median follow‐up of 18 months. Patients with clinically positive lymph nodes had 2‐year regional recurrence‐free survival rate of 78% and 73% in the definitive lymph node irradiation (n = 9) and CLND ± radiotherapy (n = 15) groups, respectively (P = .8) with a median follow‐up of 16 months. CONCLUSIONS: To the best of the authors' knowledge, the current study is the largest series published to date of radiation monotherapy as regional treatment for lymph node‐positive MCC. Lymph node irradiation alone to positive regional lymph nodes was found to confer an excellent regional control rate that was comparable to CLND for both microscopic and palpable lymph node disease. There was no difference noted with regard to overall survival. Given their similar efficacy, the choice between these lymph node therapies may be based on the clinical scenario and anticipated side effect profiles. Cancer 2010. © 2010 American Cancer Society.Keywords
This publication has 52 references indexed in Scilit:
- Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU featuresJournal of the American Academy of Dermatology, 2008
- Clonal Integration of a Polyomavirus in Human Merkel Cell CarcinomaScience, 2008
- Merkel cell carcinoma adjuvant therapy: Current data support radiation but not chemotherapyJournal of the American Academy of Dermatology, 2007
- Predictors of survival and recurrence in the surgical treatment of merkel cell carcinoma of the extremitiesJournal of Surgical Oncology, 2007
- Comparative study of lymphoedema with axillary node dissection versus axillary node sampling with radiotherapy in patients undergoing breast conservation surgeryEuropean Journal of Surgical Oncology, 2006
- Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancerBreast Cancer Research and Treatment, 2005
- High-Risk Merkel Cell Carcinoma of the Skin Treated With Synchronous Carboplatin/Etoposide and Radiation: A Trans-Tasman Radiation Oncology Group Study—TROG 96:07Journal of Clinical Oncology, 2003
- Epidemiology of primary Merkel cell carcinoma in the United StatesJournal of the American Academy of Dermatology, 2003
- Local control of primary Merkel cell carcinoma: Review of 45 cases treated with Mohs micrographic surgery with and without adjuvant radiationJournal of the American Academy of Dermatology, 2002
- Multimodality Treatment of Merkel Cell Carcinoma: Case Series and Literature Review of 1024 CasesAnnals of Surgical Oncology, 2001